A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

计划入组 213 人 · 首次发布于 2024 年 5 月 21 日

A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

计划入组 200 人 · 首次发布于 2026 年 6 月 12 日

Safety and Immunogenicity Study of Ad26-ENVA and Ad35-ENV HIV Vaccines in Healthy HIV-uninfected Adults

计划入组 218 人 · 首次发布于 2010 年 10 月 6 日

ENV-294

ENV-0205

ENV-1305

Enviva

United States

Envoy Medical Corporation

United States

ENVISION KINDNESS, INC.

United States

Enveda's ENV-294 Shows 85% EASI Reduction in Phase 1b Atopic Dermatitis Trial

Enveda's AI-Discovered Anti-Inflammatory ENV-294 Clears Phase 1 Safety Trial, Advances to Atopic Dermatitis Study

Enveda Advances First-in-Class Oral Therapy ENV-294 to Phase 2 Trials for Atopic Dermatitis and Asthma